UBE2V1 antibody (C-Term, Isoform 3)
Quick Overview for UBE2V1 antibody (C-Term, Isoform 3) (ABIN357577)
Target
See all UBE2V1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term, Isoform 3
-
Specificity
- This antibody is specific to UBE2V1 (C-term, Isoform 3). Predicted to cross react with Mouse and Zebrafish (100 % Antigen Homology).
-
Purification
- Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human UBE2V1.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- ELISA: 1/1,000. Western Blot: 1/100-1/500.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) Sodium Azide as preservative.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))
-
Alternative Name
- UBE2V1 / CROC1
-
Background
- The CROC1 isoforms, also known as UBE2V1, show sequence similarity to ubiquitin-conjugating enzymes (UBCs, or E2s) but lack the conserved cysteine residue critical to catalytic activity of E2s.1 Northern blot analysis detected approximately 2.1- and 2.5-kb CROC1 transcripts in all human tissues examined, with the highest levels in brain, skeletal muscle, and kidney. Partial human intestinal epithelial cell cDNAs have been isolated containing the 3-primecoding sequence and 3-prime untranslated region of UBE2V1, also called UEV1.2 UEV1 does not have ubiquitin-conjugating activity in vitro. UEV1 transcripts are downregulated upon differentiation of a colon carcinoma cell line.1 Constitutive expression of exogenous UEV1 protein in these colon carcinoma cells inhibits their capacity to differentiate upon confluence and induces changes in cell cycle behavior associated with inhibition of CDK1. A heterodimeric protein complex has been identified that links TRAF6 to IKK activation.3 Peptide mass fingerprinting analysis revealed that this complex is composed of the ubiquitin conjugating enzyme UBC13 and the UBC-like protein UBE2V1, also called UEV1A. TRAF6, a RING domain protein, functions together with UBC13/UEV1A to catalyze the synthesis of unique polyubiquitin chains linked through lysine-63 (K63) of ubiquitin. Blockade of this polyubiquitin chain synthesis, but not inhibition of the proteasome, prevents the activation of IKK by TRAF6. These results unveil a new regulatory function for ubiquitin, in which IKK is activated through the assembly of K63-linked polyubiquitin chains.Synonyms: CROC-1, P/OKcl.19, TRAF6-regulated IKK activator 1 beta Uev1A, UBE2V, UEV-1, UEV1, Ubiquitin-conjugating enzyme E2 variant 1
-
Molecular Weight
- 19307 Da
-
Gene ID
- 387522
-
NCBI Accession
- NP_001027459
-
UniProt
- Q13404
-
Pathways
- TCR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Toll-Like Receptors Cascades
Target
-